Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate.

Hiraku Uchimura, Kaori Kanai, Masami Arai, Miyu Inoue, Akitoyo Hishimoto, Daiki Masukawa, Yoshio Goshima

Journal of pharmacological sciences 2023 Jul

filter terms:

Methylphenidate (MPH) and methamphetamine (METH) are the current treatments of choice for attention deficit/hyperactivity disorder. We previously reported that METH induces the release of dopamine (DA) and of the neurotransmitter candidate L-3,4-dihydroxyphenylalanine (L-DOPA). In contrast, we here found that MPH increased the DA release while it did not affect the L-DOPA release from the dorsolateral striatum. Nevertheless, MPH-induced hyperlocomotion was reduced in Gpr143 (L-DOPA receptor) gene-deficient (Gpr143-/y) mice. The rewarding effect and increased c-fos expression induced by MPH were also attenuated in Gpr143-/y mice. Together, these findings suggest that GPR143 is involved in the acute and chronic actions of MPH. Copyright © 2023 The Authors. Production and hosting by Elsevier B.V. All rights reserved.

Citation

Hiraku Uchimura, Kaori Kanai, Masami Arai, Miyu Inoue, Akitoyo Hishimoto, Daiki Masukawa, Yoshio Goshima. Involvement of the L-DOPA receptor GPR143 in acute and chronic actions of methylphenidate. Journal of pharmacological sciences. 2023 Jul;152(3):178-181